WNT6 and central nervous system cancer: Concordantly, expanding a similar analysis to the cohort of TCGA glioma patients with microarray data (27 lower‐grade II and III glioma—LGG; and 368 IDHwt and 30 IDHmut GBM) confirmed the overexpression of WNT6 in higher grades of glioma, both in IDHwt and in IDHmut GBMs (Fig. 1B; of note, due to the limited number of LGG patients with available microarray data [n = 27], these cases were not subdivided according to the 2016 CNS classification).